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Background: Glutamate decarboxylase is an intracellular enzyme converting glutamate
into GABA. Antibodies (abs) to its isoform GAD65 were described in limbic encephali-
tis and other neurological conditions. The significance of GAD65 abs for epilepsy is
unclear, but alterations of inhibitory GABAergic neurotransmission may be involved. Here,
we investigated the effects of the serum of a female patient suffering from GAD65
ab-associated LE on GABAA currents in cultured hippocampal networks.
Methods: Spontaneous or evoked post-synaptic GABAA currents were measured in
cultured hippocampal neurons prepared from embryonic mice after 11–21days in vitro
using the patch-clamp technique in the whole-cell mode after incubation with serum of a
healthy control or the LE-patient at a final concentration of 1% for 5–8 h.
Results: Properties of miniature inhibitory post-synaptic currents were not different in
cultures treated with control and LE-serum. Likewise, paired-pulse ratio of evoked GABAA
currents as a measure of release probability was not different in both conditions. Evoked
GABAA currents were significantly depressed during 10Hz stimulation without significant
differences between control and LE-serum treated cultures.
Conclusion: In our experimental paradigms, serum of a patient with confirmed GAD65
ab-associated LE had no apparent effect on GABAergic neurotransmission in murine-
cultured hippocampal networks. These results challenge the view that the presence of
GAD65 abs invariably compromise inhibitory network function.
Keywords: GAD65 antibodies, limbic encephalitis, GABAergic neurotransmission, hippocampal cultures, GABA(A)
currents
Introduction
Limbic encephalitis (LE) is clinically characterized by new onset of temporal lobe seizures as
well as disturbances of mood and memory function. An increasing number of different auto-
antibodies (abs) are detected in the serum and cerebrospinal fluid (CSF) of affected people. These
abs include classical onconeuronal abs, but also directly target neuronal structures in extracellular
and intracellular compartments (1).
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Neuronal abs associated with LE typically bind to structures
which are involved in the process of synaptic transmission or
modulation of neuronal excitability. Extracellular antigens at the
cell surface comprise NMDA receptors, components of voltage-
gated potassium channels (VGKCs) aswell asGABAA andGABAB
receptors, which are likely to alter neurotransmission or neu-
ronal excitability (2–4). At least for abs against NMDA and
GABAA receptors, abnormally impaired neurotransmission was
recently shown in in vitro experiments mainly by internaliza-
tion of the receptors and subsequently reduced ionic conduc-
tances (5–7). Abs against VGKCs appear to enhance synaptic
transmission (8).
In contrast to the aforementioned surface antigens, glutamate
decarboxylase (GAD) is an intracellular enzyme that converts the
excitatory neurotransmitter glutamate into the inhibitory neuro-
transmitter GABA. Two isoforms of GAD are expressed in the
brain, a 67 kDa isoform (GAD67) and a 65 kDa isoform (GAD65)
(9). Interestingly, defects in GAD65 activity were associated with
recurrent seizures in GAD65 knock-out mice (10). Abs against
GAD65were detected in the serum or CSF of people with diabetes
mellitus type I, LE and other neurological conditions, such as stiff
person syndrome (SPS) or cerebellar ataxia (11, 12). In view of the
molecular weight and dimensions of IgG abs and the intracellular
localization of GAD65 in synaptic terminals, it remains to be
determinedwhetherGAD65 abs interfere withGABAergic neuro-
transmission in the brain, thereby possibly enhancing excitability
of neuronal networks and contributing, e.g., to the generation
of epileptic seizures. From a clinical point of view, this question
may be relevant when selecting immunomodulatory treatment
options. If GAD65 abs do not directly influence brain function,
they may rather reflect an epiphenomenon of the underlying
autoimmune process and ab-removal by plasma exchangemay not
be helpful.
Previous experimental studies suggest that GAD65 abs can
indeed interfere with GABAergic signaling. First, GAD65 abs
inhibit enzymatic GAD65 activity (13, 14). Second, GAD65 abs
can cross the blood–brain barrier, reach the brain tissue and
appear to be bound and taken up by hippocampal neurons
(15–17). Third, serum or CSF from patients with SPS or progres-
sive cerebellar ataxia and GAD65 abs led to a rapid and reversible
pre-synaptic inhibition of GABA release in rat cerebellar slices
within 10–15min upon acute application (18–21). Furthermore,
the serum of an epilepsy patient with GAD65 abs induced a
twofold increase of network activity of hippocampal cultures
within 2–3min after application (22). Finally, passive transfer
experiments in rats showed that intracerebellar, intraventricular,
or intrathecal administration of IgG abs from patients with SPS or
cerebellar ataxia and GAD65 abs induced motor dysfunction in
rats (23, 24).
Taken together, previous studies support the notion that
abs targeting the intracellular GAD65 enzyme possibly alter
inhibitory neurotransmission in people with LE and thereby
facilitate the generation of recurrent epileptic seizures. Here,
we investigated the effects of the serum from a female patient
suffering from GAD65 ab-associated LE on spontaneous and
evoked GABAergic neurotransmission in cultured hippocampal
neurons.
Materials and Methods
Detection of Antibodies
Identification of GAD65 abs was performed by radioimmuno-
precipitation assay (RIA) using 125I-GAD (normal values
<1U/ml, laboratory of Professor Angela Vincent, Weatherall
Institute, Oxford, UK) or by indirect immunofluorescence
test (IFT, normal values <1:10, EUROIMMUN Laboratory,
Luebeck, Germany) and enzyme-linked immunosorbent assay
(ELISA, normal values <10 IU/ml, EUROIMMUN). Presence
of VGKC-abs was tested by RIA (normal values <100 pmol/l,
laboratory of Professor Angela Vincent and EUROIMMUN) and
NMDAR-abs were tested by specific IFT (laboratory of Professor
Angela Vincent).
Cell Cultures
Primary neuronal cultures were prepared from fetal (E16–E19)
mice brains (C57BL/6N). Embryo heads were dissected and
placed in ice-cold dissectionmedium (HBSS and 20% fetal bovine
serum). The meninges were cautiously removed and the cortex
and hippocampus of every pup were isolated and separately col-
lected. Trypsin was added to a final concentration of 0.05% and
incubated for 10min at 37°C. Subsequently, the enzyme solu-
tion was removed, the preparations were washed and the gently
dissociated cells were plated on coverslips coated with poly--
lysine. Hippocampal neuronswere grown in Eagle’s BasalMedium
supplemented with 2% B27, 1% fetal bovine serum, 0.45% glu-
cose, and 0.2mM -glutamine at 37°C and 95% O2/5% CO2.
After 11–21 days in vitro, neuronal cultures were incubated with
patient serum (containing more than 2000 IU/ml GAD65 IgG
abs according to ELISA; see also Section “Results”) or control
serum (a healthy 23-year-old woman) at a final concentration of
1% for 5–8 h prior to patch-clamp recordings. Experiments were
performed for each condition in a blinded fashion (experiments
and analysis of the raw data was performed blinded to the origin
of the applied serum). Furthermore, experiments were matched
for days in vitro and cell culture batch, i.e., both control and
LE-serum were tested in cell cultures of the same batch and at
the same days in order to avoid age- or maturation-dependent
effects. All animal experiments were conducted in accordance
with the guidelines of the Animal Care and Use Committee of the
University of Bonn. The study was approved by the Local Ethics
Committee and written informed consent was obtained from the
patient.
Electrophysiology
Cells were visualized using an inverse microscope (Axiovert 40
CFL, Zeiss, Jena, Germany). Somatic whole-cell voltage-clamp
recordings weremade with a HEKAEPC-9 patch-clamp amplifier
(HEKA Electronics, Lambrecht, Germany). Electrode resistance
in the bath varied between 3 and 4MΩ. Series resistancewasmon-
itored throughout the experiment. Data were sampled at 10 kHz
and filtered at 1 kHz. Holding potential was corrected on-line for
liquid junction potentials.
To record miniature IPSC (mIPSCs), cells were held at
 60mV. Bath solution consisted of (in mM) 125 NaCl; 2.5 KCl;
2 CaCl2; 2 MgCl2; 30 glucose; and 25 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) (pH adjusted to 7.4,
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osmolality to 310mOsmol). Overlapping excitatory ligand-gated
currents and voltage-gated sodium channels were blocked by
bath-application of 20μM( )-2-amino-5-phosphonopentanoic
acid (AP5), 10μM 6-cyano-7-nitroquinoxaline-2,3-dione
(CNQX) and 1μM tetrodotoxin (TTX). Internal solution
consisted of (mM) 135 KCl, 10 HEPES, 5 Na2-Phosphocreatine,
2 EGTA, 4Mg-ATP, and 0.5 Na2-GTP (pH adjusted to 7.3 and
osmolality to 290–300mOsmol).
Evoked IPSC were stimulated with a bipolar electrode (Royem
Scientific Limited, UK, FHC; CBAEC75 – concentric bipolar elec-
trode) placed close to the recorded neuron (25). The position
of the stimulation electrode was kept unchanged during indi-
vidual experiments at a distance of about 300μm to the post-
synaptic neuron. In most experiments, stimulation currents were
set to an amplitude of 1mA and a duration of 1ms at a fre-
quency of 10Hz using an external pulse generator (A-M Systems,
Inc., Carlsborg, USA Isolated Pulse Stimulator, Model 2100).
Bath solution was continuously oxygenated with 95% O2/5%
CO2 and consisted of (mM) 125 NaCl, 3.5 KCl, 2 CaCl2, 1
MgCl2, 15 Glucose, 1.25 NaH2PO4, and 26NaHCO3 (pH adjusted
to 7.4, osmolality 310mOsmol). To block overlapping excita-
tory currents, bath solution contained 20μM AP5 and 10μM
CNQX. Internal solution consisted of (mM) 130 KCl; 5 Na2-
Phosphocreatine; 10 HEPES; 2 EGTA; 4Mg-ATP; 0.5 Na2GTP;
and 5 lidocaine N-ethyl-chloride to block voltage-gated sodium
currents (pH adjusted to 7.3 and osmolality to 290–300mOsmol).
Holding potential was set to 60mV.
Data Analysis
Miniature IPSCs were automatically detected using an algorithm,
which measured the peak amplitude and rise and decay times.
Undetected events and false positives were corrected by visual
inspection. Amplitudes of evoked IPSC were determined from
baseline to themaximal downward deflection. Statistics were done
using Mann–Whitney tests. Data are given as mean SEM.
Results
Clinical Case
A 45-year-old female patient presented with temporal lobe
seizures since the age of 43 years, a moderate depression as well as
predominant deficits in visual memory pointing toward disturbed
function of the right temporal lobe. Cerebral magnetic resonance
imaging (MRI) at the time of disease-onset revealed increased
volume and signal intensity in both temporo-mesial structures
(amygdala and hippocampus), whereas 2 years later, MRI abnor-
malities persisted in the left mesial temporal lobe only with appar-
ent regression on the right hemisphere (Figure 1A). In line with
the MRI findings, cerebral 18-fluorodeoxyglucose-positron emis-
sion tomography (FDG-PET) showed decreased hypometabolism
FIGURE 1 | (A) Coronal T2-weighted cerebral MRI shows increased volume and
signal in the left amygdala and anterior part of the hippocampus (indicated by
asterisk). (B) FDG-PET displays hypometabolism in both temporo-mesial
regions with a predominant deficit in the left hemisphere (indicated by asterisks:
left panel coronal section and right panel axial section). (C) Interictal scalp EEG
in bipolar montage shows sharp-slow-wave activity in the right fronto-temporal
region (indicated by asterisk). (D) Ictal scalp EEG of a typical temporal lobe
seizure demonstrates seizure-onset over the right temporal region with a
regional maximum at the electrodes T6, T4, and T2 (unipolar montage against
common average).
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in both mesial temporal lobes with a more pronounced deficit in
the left temporal lobe (Figure 1B). Interictal scalp EEG displayed
intermittent sharp-slow-wave complexes over the right fronto-
temporal region during sleep (Figure 1C). Furthermore, a typ-
ical temporal lobe seizure was recorded from wakefulness with
onset over the right temporal region (Figure 1D). In comple-
mentary analyses, GAD65 abs were detected in both serum (titer
>1000U/ml; later on >2000 IU/ml) and CSF (9.2U/ml) along
with oligoclonal bands in the CSF. Abs against NMDA recep-
tors or VGKCs were not found. An extended search for tumors
remained negative. The final diagnosis of non-paraneoplastic
GAD65 ab-associated LE was made and immunomodulatory
therapy over a time period of 2 years, including plasma exchange
as well as administration of cyclophosphamide, cortisone, and
mycophenolate mofetil, was started. In the further course, epilep-
tic seizures proved to be difficult to treat (anticonvulsant drugs
used until the last follow-up 5 years after onset of LE included
lacosamide, lamotrigine, levetiracetam, oxcarbazepine, peram-
panel, pregabalin, topiramate, valproic acid, and zonisamide).
Spontaneous GABAergic Currents in Cultured
Hippocampal Neurons
Recordings were made in primary neuronal cultures after
11–21 days in vitro (Figure 2A). Spontaneous mIPSC were
recorded during a time period of 5min. Application of 20μM
bicuculline completely and reversibly blocked mIPSC
(Figures 2B,C). To examine the effects of the serum of the
above mentioned LE-patient (containing a GAD65 ab titer above
2000 IU/ml) on mIPSC, neuronal cultures were incubated with
control or LE-serum at a final concentration of 1% for 5–8 h prior
to recordings. Neither amplitudes of mIPSC (p= 1.0; control
28.5 2.25 pA; LE-serum 25.9 2.25 pA; 10 recordings each
condition) nor inter-event intervals (p= 0.27; control 1.53
0.49 s, LE-serum 1.98 0.50 s; 10 recordings each condition)
were different in both conditions (Figures 2D,E).
Evoked GABAergic Currents in Cultured
Hippocampal Neurons
To test whether LE-serum affects GABAergic neurotransmission
upon repetitive neuronal activity, a method to evoke synaptic
release in neuronal cell cultures was established [see Section
“Materials and Methods” and Figures 3A,B (25)]. To ascer-
tain that GABAergic currents were measured in the experimen-
tal configuration, the calculated reversal potential for chloride
( 0.09mV) was compared to the experimentally determined
reversal potential of the recorded post-synaptic currents (+4mV,
Figure 3C). Then, neuronal cultures were incubated for 5–8 h
with control and LE-serum and GABAergic synaptic terminals
were challenged by repetitive extracellular stimulation at 10Hz
for 2min in both conditions (Figure 3D). Paired-pulse ratio
(PPR, ratio of second to first pulse) as a measure of pre-synaptic
release probability did not differ between control and LE-serum
(p= 0.74; control 1.33 0.28, 7 recordings; LE-serum 1.13 0.17,
10 recordings). Evoked GABAA currents were depressed during
10Hz stimulation without significant differences between control
and LE-serum treated cultures (synaptic depression at pulse 120
with respect to the first pulse: control 44.2 16.8%, LE-serum
56.0 13.4%, p= 0.47; at pulse 240: control 57.4 13.0% LE-
serum 67.1 8.7%, p= 0.31; control 7 recordings, LE-serum 10
recordings; Figure 3E).
FIGURE 2 | (A) Sketch of the experimental configuration. Miniature IPSCs
are recorded with the help of a patch-clamp electrode in whole-cell mode in
the presence of AP5, CNQX, and TTX in the bath solution (post-synaptic
neuron in blue). (B) Original mIPSC traces before (upper panel), during
(middle panel), and after application (lower panel) of 20μM bicuculline to
block GABAA receptors. Inset displays enlarged control mIPSC, scaling
100pA/100ms. (C) Bicuculline completely blocked recorded post-synaptic
currents (four recordings). (D) Original mIPSC-traces after incubation with
control serum (upper panel) and patient serum (lower panel) both at a final
concentration of 1%. (E) Amplitudes of mIPSC (left panel) and inter-event
intervals (right panel) were not different after incubation with control and
patient serum (10 recordings each condition).
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FIGURE 3 | (A) Sketch of the experimental configuration. Evoked IPSCs
were stimulated by an extracellular concentric bipolar electrode placed
nearby the axons of surrounding neurons (in red and green) in the presence
of AP5 and CNQX in the bath solution. The post-synaptic neuron (in blue)
contained lidocaine to block voltage-gated sodium channels. (B) Original
traces of evoked IPSC during extracellular repetitive stimulation at 0.1Hz.
Inset shows an enlarged evoked IPSC (asterisk indicate stimulation artifacts).
(C) Amplitudes of evoked IPSC were measured at different holding
potentials to determine the reversal potential (four recordings). (D) Original
traces of evoked IPSC-traces during repetitive extracellular stimulation at
10Hz for 2min after incubation with control serum (left traces) and patient
serum (right traces) at different time points. This figure illustrates the high
variability between IPSC recordings from different cells (see also Section
“Discussion”). (E) Paired-pulse ratio (PPR, ratio of second to first pulse; left
panel) and post-synaptic depression at different time points (after 120 and
240 pulses, right panel) upon repetitive 10-Hz stimulation for 2min were not
different after incubation with control (7 recordings) and patient serum
(10 recordings).
Discussion
Previous studies in GAD65 knock-out mice suggested that the
two isoforms of the GAD-enzyme, GAD65, and GAD67, have
distinct roles in GABAergic neurotransmission: whereas GAD67
provides GABA for basal neurotransmission, GAD65 appears to
be predominantly involved in the GABA synthesis upon sustained
neuronal activity (26). In light of these findings, the lack of effects
on mIPSC by the LE-serum during sparse, spontaneous activity
may not be surprising. However, GABAergic transmission evoked
with trains of electrical stimulation was also not affected by the
LE-serum.
Our findings are at oddswith the results of previous experimen-
tal studies which demonstrated a clear inhibition of GABAergic
neurotransmission by serum, CSF or purified IgG in rat cerebellar
slices (18–21). The lack of unequivocal alterations of GABAergic
currents in our study could be due to the apparently high variabil-
ity of the recorded post-synaptic currents and the relatively small
sample size. In contrast to experiments using anatomically more
intact neuronal preparations, such as hippocampal slices, neu-
ronal cultures display a considerable variability (with respect to
cellular composition, number of synaptic connections per neuron,
etc.) and do not allow the unequivocal selection and identification
of the same cell types. Thus, post-synaptic currents considerably
varied from recording to recording in our experiments, as illus-
trated in Figure 3D, and may have masked a more subtle effect
of GAD65 abs on GABAergic neurotransmission. The absence of
clear-cut effects in our study is unlikely to be simply due to issues
related to the concentration and duration of application. In our
experiments, we have diluted the serum to a final concentration of
1%, which is similar to that in other studies (e.g., 18, 20). Higher
concentrations of the patient’s serum (e.g., 2 or 10%) could have
had measurable effects on GABAergic neurotransmission, but we
have not tested this in our experiments. Regarding the duration of
application, our neuronal cultures were pre-incubated for 5–8 h
with the control and patient serum. Neuronal uptake of IgG abs
was previously shown in cultured hippocampal neurons with a
maximum after 4 h (15), well within our incubation times. It is
theoretically possible that the human autoantibodies were not
active in our study due to weak cross-reactivity between species.
However, this has not been an issue in other cross-species studies
that have claimed activity of patient serum or patient-derived abs
in rodent preparations (18–21). Nevertheless, due to the lack of
clear-cut effects on GABAergic neurotransmission, we have not
performed further experiments to elucidate possible causes (i.e.,
we have not performed complementary immunohistochemical
stainings to demonstrate failed neuronal uptake of abs or addi-
tional biochemical studies in order to investigate serum effects
on enzyme activity of GAD65). One potential experimental con-
founder is the use of whole blood serum instead of purified abs.
The patient serum contained the anticonvulsant drug levetirac-
etam at a concentration of about 150μM, which was diluted to a
final concentration of 1.5μM. Levetiracetam binds to the synaptic
vesicle protein 2A (SV2A) and presumably inhibits pre-synaptic
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calcium channels (27). In addition, run-down of GABAA currents
upon repetitive stimulation was attenuated in a Xenopus oocyte
preparation by levetiracetam at low concentrations (28). The
efficacious concentrations of levetiracetam, however, typically
range from 35 to 100μM (27), which makes it very unlikely that
levetiracetam has exerted a measurable effect in our experiments.
Despite the limitations of the present study, our results sug-
gest that GAD65 abs do not invariably modulate GABAergic
neurotransmission in all patients that display these autoantibod-
ies. This finding is supported by a recent experimental study,
demonstrating that sustained GABAergic transmission and pre-
synaptic GABAergic vesicle pool size remained unchanged upon
application of IgG abs from SPS-patients with GAD65 abs (29). In
other patients, however, clonally unrelated GAD65 abs may well
interfere with GABAergic neurotransmission. LE associated with
GAD65 abs may be heterogeneous with respect to the functional
impact of GAD65 abs. This also suggests that it may be important
to search for other inflammatory pathways, perhaps involving
cellular or innate immunity thatmay play a role in the pathophysi-
ology of altered hippocampal excitability in GAD65 ab-associated
LE. In addition, regardless of whether GAD65 abs are functionally
relevant as inhibitors of the GABA system, the diagnostic use as
a biomarker for LE is still highly relevant, as it helps to make an
early and correct diagnosis. Furthermore, the type of ab appears
to have prognostic value and to predict the clinical course of the
disease (30).
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